SWM
PTCT icon

SeaCrest Wealth Management’s PTC Therapeutics PTCT Stock Holding History

SeaCrest Wealth Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-264
Closed -$10K – 1521
2019
Q1 		$10K Buy
+264
New +$8.86K ﹤0.01% 1532

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

SeaCrest Wealth Management's PTCT Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of PTC Therapeutics (PTCT) in Q2 2019, closing a stake of 264 shares — an estimated $10K sold.

SeaCrest Wealth Management first reported a position in PTCT in Q1 2019 and held it in 1 quarter. The position peaked at $10K in Q1 2019. 176 funds tracked by Wall St. Rank hold PTCT as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining PTC Therapeutics position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 264 PTC Therapeutics shares in Q2 2019, an estimated $10K.
  • SeaCrest Wealth Management first reported a position in PTC Therapeutics in Q1 2019 and held it in 1 quarter.
  • SeaCrest Wealth Management's PTC Therapeutics position peaked at $10K in Q1 2019.
  • 176 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.